Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis
Y Suzuki, K Mori, Y Aono, M Kono, H Hasegawa… - Scientific Reports, 2021 - nature.com
Antifibrotic therapy (AFT) slows disease progression in patients with idiopathic pulmonary
fibrosis (IPF). The Gender-Age-Physiology (GAP) index, was developed based on data at …
fibrosis (IPF). The Gender-Age-Physiology (GAP) index, was developed based on data at …
Body mass index and mortality in patients with idiopathic pulmonary fibrosis
M Alakhras, PA Decker, HF Nadrous, M Collazo-Clavell… - Chest, 2007 - Elsevier
Background To examine the relationship between body mass index (BMI) and mortality in
patients with idiopathic pulmonary fibrosis (IPF). Methods We studied a cohort of patients …
patients with idiopathic pulmonary fibrosis (IPF). Methods We studied a cohort of patients …
Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients
T Kulkarni, K Yuan, TK Tran-Nguyen, Y Kim… - PLoS …, 2019 - journals.plos.org
Background The processes that result in progression of idiopathic pulmonary fibrosis (IPF)
remain enigmatic. Moreover, the course of this disease can be highly variable and difficult to …
remain enigmatic. Moreover, the course of this disease can be highly variable and difficult to …
Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the …
J Behr, A Prasse, H Wirtz, D Koschel… - European …, 2020 - Eur Respiratory Soc
Objective There is a paucity of observational data on antifibrotic therapy for idiopathic
pulmonary fibrosis (IPF). We aimed to assess the course of disease of IPF patients with and …
pulmonary fibrosis (IPF). We aimed to assess the course of disease of IPF patients with and …
[HTML][HTML] How does comorbidity influence survival in idiopathic pulmonary fibrosis?
C Hyldgaard, O Hilberg, E Bendstrup - Respiratory medicine, 2014 - Elsevier
Introduction Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic
interstitial pneumonias. It is a serious and progressive lung disease with a median survival …
interstitial pneumonias. It is a serious and progressive lung disease with a median survival …
Fat-free mass index controlled for age and sex and malnutrition are predictors of survival in interstitial lung disease
Background: Literature focusing on nutritional variables and survival in interstitial lung
disease (ILD) is limited by its focus on weight and BMI and has not considered body …
disease (ILD) is limited by its focus on weight and BMI and has not considered body …
[HTML][HTML] Body mass index—percent forced vital capacity—respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients
T Kishaba, H Nagano, Y Nei… - Journal of Thoracic …, 2016 - ncbi.nlm.nih.gov
Background Idiopathic pulmonary fibrosis (IPF) is relentless progressive interstitial lung
disease. Evaluating predictor of mortality for IPF patients is crucial. The aim of this study was …
disease. Evaluating predictor of mortality for IPF patients is crucial. The aim of this study was …
Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis
MI Lassenius, I Toppila, N Pöntynen… - European clinical …, 2020 - Taylor & Francis
Aim of the study: Potential care implications of antifibrotic reimbursement restrictions were
studied by forced vital capacity (FVC) decline, mortality and specialty care related healthcare …
studied by forced vital capacity (FVC) decline, mortality and specialty care related healthcare …
[HTML][HTML] Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study
Rationale Longitudinal data on the impact of continued, switched or discontinued antifibrotic
therapy in patients with idiopathic pulmonary fibrosis (IPF) who have disease progression is …
therapy in patients with idiopathic pulmonary fibrosis (IPF) who have disease progression is …
Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis
WM Reichmann, YF Yu, D Macaulay, EQ Wu… - BMC pulmonary …, 2015 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is a rare and serious disease characterized
by progressive lung-function loss. Limited evidence has been published on the impact of …
by progressive lung-function loss. Limited evidence has been published on the impact of …